The hemodialysis and peritoneal dialysis market in Asia Pacific is expected to grow from US$ 19,255.20 million in 2022 to US$ 29,972.11 million by 2028; it is estimated to grow at a CAGR of 7.7% from 2022 to 2028.
The increasing preference for home care dialysis is the major factor driving the Asia Pacific hemodialysis and peritoneal dialysis market. Home hemodialysis (HHD) is a kidney replacement modality for patients with end-stage kidney disease (ESKD) that can be performed safely in the patient’s home environment. It requires the assistance of a trained caregiver or qualified hemodialysis nurse. The frequency of treatment for HHD can vary as per the patient. HHD can be performed as conventional HHD, with treatments 3 days a week for 3 to 4 hours or longer each time. It can also be performed as a short daily HHD, occurring 5 to 7 times a week for a shorter duration. Lastly, it can be performed overnight as nocturnal HHD, where treatments normally last 6 to 8 hours. New, easy-to-use machines are being developed for home hemodialysis. These are easier to set up, clean, and disinfect. Although the increasing reimbursement of home dialysis would seem to be an appropriate strategy to stimulate uptake of these modalities, evidence from regions that offer high reimbursement rates for peritoneal dialysis (PD) suggests that the success of this strategy is variable.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Asia Pacific hemodialysis and peritoneal dialysis market. The Asia Pacific hemodialysis and peritoneal dialysis market is expected to grow at a good CAGR during the forecast period.
The increasing preference for home care dialysis is the major factor driving the Asia Pacific hemodialysis and peritoneal dialysis market. Home hemodialysis (HHD) is a kidney replacement modality for patients with end-stage kidney disease (ESKD) that can be performed safely in the patient’s home environment. It requires the assistance of a trained caregiver or qualified hemodialysis nurse. The frequency of treatment for HHD can vary as per the patient. HHD can be performed as conventional HHD, with treatments 3 days a week for 3 to 4 hours or longer each time. It can also be performed as a short daily HHD, occurring 5 to 7 times a week for a shorter duration. Lastly, it can be performed overnight as nocturnal HHD, where treatments normally last 6 to 8 hours. New, easy-to-use machines are being developed for home hemodialysis. These are easier to set up, clean, and disinfect. Although the increasing reimbursement of home dialysis would seem to be an appropriate strategy to stimulate uptake of these modalities, evidence from regions that offer high reimbursement rates for peritoneal dialysis (PD) suggests that the success of this strategy is variable.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Asia Pacific hemodialysis and peritoneal dialysis market. The Asia Pacific hemodialysis and peritoneal dialysis market is expected to grow at a good CAGR during the forecast period.
Asia Pacific Hemodialysis and Peritoneal Dialysis Market Segmentation
The Asia Pacific hemodialysis and peritoneal dialysis market is segmented into type, product, end user, and country.- Based on type, the market is bifurcated into hemodialysis and peritoneal dialysis. In 2022, the hemodialysis segment is expected to hold a larger market share.
- Based on product, the hemodialysis and peritoneal dialysis market is segmented into devices, consumables, and services. The services segment is likely to hold the largest market share in 2022.
- Based on end user, the market is segmented into hospital-based and home-based. The hospital-based segment is expected to account for a larger share in 2022.
- Based on country, the Asia Pacific hemodialysis and peritoneal dialysis market is segmented into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China is anticipated to hold the largest market share in 2022.
Table of Contents
1. Introduction
3. Research Methodology
4. APAC Hemodialysis and Peritoneal Dialysis Market - Market Landscape
5. APAC Hemodialysis and Peritoneal Dialysis Market - Key Market Dynamics
6. Haemodialysis and Peritoneal Dialysis Market- APAC Analysis
7. APAC Haemodialysis and Peritoneal Dialysis Market Revenue and Forecasts To 2028- by Type
8. APAC Haemodialysis and Peritoneal Dialysis Market Revenue and Forecasts To 2028 - Product
9. APAC Haemodialysis and Peritoneal Dialysis Market Revenue and Forecasts To 2028 - End User
10. APAC Haemodialysis and Peritoneal Dialysis Market Revenue and Forecasts to 2028 - Country Analysis
11. Hemodialysis and Peritoneal Dialysis Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Asahi Kasei Medical Co., Ltd.
- B. Braun Melsungen AG
- Baxter International Inc.
- DaVita Inc.
- Dialife SA
- Diaverum
- Fresenius Medical Care AG & Co KGaA
- Nipro Medical Corporation
- Rockwell Medical, Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 73 |
| Published | September 2022 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 19255.2 Million |
| Forecasted Market Value ( USD | $ 29972.11 Million |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Asia Pacific |
